The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

最新公布的结果是一项名为PURPOSE 1的III期、双盲、随机研究，旨在评估Lenacapavir和Descovy对5,300多名16~25岁女性的安全性和有效性。 这5,300多名受试者 ...

Descovy and Truvada are prescription drugs used to treat and help prevent HIV. Both drugs come as oral tablets that are taken once per day. Truvada is available as a generic drug, while Descovy is ...

Two oral PrEP medications have been approved by the U.S. Food and Drug Administration (FDA)—Truvada and Descovy—and one injection drug called Apretude that must be taken once every two months.

Gilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – but as expected its use in women was a point of contention. Descovy ...

In this month’s issue, the Sexpert advises readers on how to navigate discussions of PrEP and sexual health while in the ...

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six months.

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

The government said in a pre-trial court filing it was entitled to up to $691 million in damages from Truvada and $311 million from Gilead's related drug Descovy. Gilead earned more than $1.8 ...